Loading…
Tempest Therapeutics, Inc. is projected to decline to $0.9578 by 2027, a -2% move from its current price of $0.973. TPST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.9405 | $0.9728 | $1.01 | -0.02% |
| Jul 14 | $0.9272 | $0.9726 | $1.02 | -0.04% |
| Jul 15 | $0.9171 | $0.9724 | $1.03 | -0.06% |
| Jul 16 | $0.9087 | $0.9722 | $1.04 | -0.08% |
| Jul 17 | $0.9013 | $0.972 | $1.05 | -0.10% |
| Jul 18 | $0.8946 | $0.9718 | $1.06 | -0.12% |
| Jul 19 | $0.8885 | $0.9716 | $1.06 | -0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8885 | $0.9716 | $1.06 | -0.14% |
| Week 2 | $0.855 | $0.9703 | $1.10 | -0.28% |
| Week 3 | $0.8299 | $0.9689 | $1.13 | -0.42% |
| Week 4 | $0.8091 | $0.9675 | $1.16 | -0.56% |
| Week 5 | $0.7911 | $0.9662 | $1.18 | -0.70% |
| Week 6 | $0.7751 | $0.9648 | $1.20 | -0.84% |
| Week 7 | $0.7605 | $0.9635 | $1.22 | -0.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Tempest Therapeutics, Inc. trades in the healthcare sector under the symbol TPST. The stock’s current price is $0.9748, with a market capitalization of $15.58M and a market rank of 5003.
Near-term outlook shows limited upside, with the 2026 forecast range from a min of $0.9748 to a max of $1.20 and an average price of $0.9748, implying an ROI of 0 in that year. The forecast then spans multiple years with varying sentiment and returns, including a bearish view in 2030 and bullish views in 2032, 2040 and beyond, up to 2050 with notable upside potential.
A major floor 51.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 77.8% above — a clean break opens room to run.
A major ceiling 146.7% above — clearing it would confirm fresh momentum.
Key TPST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TPST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9992 | Sell | $1.00 | Sell |
| MA 10 | $1.05 | Sell | $1.05 | Sell |
| MA 20 | $1.13 | Sell | $1.14 | Sell |
| MA 50 | $1.49 | Sell | $1.42 | Sell |
| MA 100 | $1.77 | Sell | $2.00 | Sell |
| MA 200 | $3.83 | Sell | $3.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 22.66 | Buy |
| Stoch RSI (14) | 1.58 | Buy |
| CCI (20) | -114.08 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -22.47 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.47 | Sell |
| Awesome (5,34) | -0.28 | Sell |
| Ultimate (7,14,28) | 7.90 | Buy |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.95 | Buy |
| ADX (14) | 41.67 | Sell |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is Neutral. The RSI(14) is 20, indicating subdued momentum. The 50-day simple moving average sits at $1.51 and the 200-day simple moving average at $3.88.
Immediate support is cited at $0.975 and resistance at $1.79. The 30-day price range runs from $0.7747 to $1.23, and the stock exhibits high annualized volatility at 70%. These numbers frame a cautious near-term outlook, with limited upside potential suggested in the immediate window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.973 | $0.973 | $1.20 | 0% | Neutral | |
| $0.7457 | $0.9578 | $1.31 | -2% | Neutral | |
| $0.6882 | $0.9157 | $1.31 | -6% | Neutral | |
| $0.6327 | $0.8673 | $1.28 | -11% | Neutral | |
| $0.5821 | $0.8191 | $1.25 | -16% | Bearish | |
| $0.6919 | $0.9974 | $1.56 | +3% | Neutral | |
| $0.7945 | $1.17 | $1.87 | +20% | Bullish | |
| $0.7369 | $1.11 | $1.81 | +14% | Neutral | |
| $0.74 | $1.14 | $1.89 | +17% | Neutral | |
| $0.6973 | $1.09 | $1.85 | +12% | Neutral | |
| $0.936 | $1.60 | $2.91 | +65% | Bullish | |
| $1.30 | $2.61 | $5.26 | +169% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.973 | $0.973 | $1.20 | +0.00% |
| August 2026 | $0.8277 | $0.9831 | $1.20 | +1.04% |
| September 2026 | $0.7973 | $0.9553 | $1.19 | -2.82% |
| October 2026 | $0.8042 | $0.9708 | $1.22 | +1.62% |
| November 2026 | $0.8015 | $0.9738 | $1.23 | +0.30% |
| December 2026 | $0.7667 | $0.9371 | $1.20 | -3.77% |
Click any year to see its month-by-month TPST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TPST could reach as high as $1.20, with a base case around $0.973 and support toward $0.973 — roughly 0% from $0.973. Price action looks broadly range-bound.
Expect TPST to range from $0.7457 to $1.31 through 2027. The $0.9578 average target implies a -2% move from current prices. That is -2% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The TPST price prediction for 2028 points to an average of $0.9157 (low $0.6882, high $1.31) — a potential decline of -6% on today's $0.973. Price action looks broadly range-bound.
In 2029, TPST is projected to trade between $0.6327 and $1.28, averaging $0.8673 — a potential decline of -11% from today's $0.973. That is -5% versus the projected 2028 average. A consolidation phase looks the most probable path here.
Tempest Therapeutics, Inc.'s 2030 outlook centres on $0.8191, within a $0.5821 to $1.25 range. That is -6% versus the projected 2029 average. That marks a -16% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2031, TPST could reach as high as $1.56, with a base case around $0.9974 and support toward $0.6919 — roughly +3% from $0.973. A consolidation phase looks the most probable path here.
Expect TPST to range from $0.7945 to $1.87 through 2032. The $1.17 average target implies a +20% move from current prices. That is up +17% on the projected 2031 average. Momentum favours further upside here.
The TPST price prediction for 2033 points to an average of $1.11 (low $0.7369, high $1.81) — a potential gain of +14% on today's $0.973. A consolidation phase looks the most probable path here.
In 2034, TPST is projected to trade between $0.74 and $1.89, averaging $1.14 — a potential gain of +17% from today's $0.973. That is up +2% on the projected 2033 average. Price action looks broadly range-bound.
Tempest Therapeutics, Inc.'s 2035 outlook centres on $1.09, within a $0.6973 to $1.85 range. That is -4% versus the projected 2034 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, TPST could reach as high as $2.91, with a base case around $1.60 and support toward $0.936 — roughly +65% from $0.973. Momentum favours further upside here.
Expect TPST to range from $1.30 to $5.26 through 2050. The $2.61 average target implies a +169% move from current prices. That is up +63% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TPST today (≈ 1,027.749229 TPST) could be worth
$2,685.7
+$1,685.7 (+169%) by 2050 · US Dollar
Based on the average projected TPST price of $2.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TPSTwould be worth at today's price.
$1,000 invested in TPST on Jul 10, 2025 (≈ 135.869563 TPST) would be worth
$132.2
-$867.8 (-86.8%) today · 0.13× · US Dollar
Based on a TPST entry price of $7.36 vs. today's $0.973.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.09 | $892.66 | -10.7% |
| 1 month ago | $1.27 | $766.14 | -23.4% |
| 3 months ago | $2.05 | $474.63 | -52.5% |
| 6 months ago | $2.86 | $340.21 | -66.0% |
| 1 year ago | $7.36 | $132.2 | -86.8% |
| All time (5.0y) ago | $267.67 | $3.64 | -99.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TPST forecast.
Our base-case forecast reaches $1.90 around 2050.
Implied market cap at $1.90: $30.36M
Looking across the multi-year forecast, 2030 shows a Bearish posture with a min of $0.5764, an average of $0.817 and a max of $1.25, yielding a -16.2 in ROI. In 2031 the sentiment shifts to Neutral with an average of $0.9964 and a max of $1.57 (ROI 2.2). The following year, 2032, turns Bullish with a $1.17 average and $1.89 max (ROI 20.2).
2033, 2034 and 2035 hover in Neutral territory with averages of $1.11, $1.13 and $1.09 respectively, and maxes of $1.83, $1.90 and $1.86 (ROI 14, 16.4 and 11.6). The forecast turns more positive in 2040, showing a Bullish outlook with an average of $1.60 and a max of $2.94 (ROI 64.5). By 2050 the outlook remains Bullish, with an average of $2.61 and a max of $5.32 (ROI 167.8).
These are estimates, not guarantees, and reflect modeled paths with varying levels of risk.
Tap a question to reveal the answer.
Min $0.5764, Avg $0.817, Max $1.25; ROI -16.2; Sentiment BEARISH.
Forecasts show mixed signals: near-term Neutral in 2026 with ROI 0 and later years showing Neutral (2031-2035) and Bullish (2040, 2050) with higher ROIs (64.5 in 2040 and 167.8 in 2050). The 2030 Bearish reading also appears in the forecast.
Yes. The forecast includes a 2040 max of $2.94 and a 2050 max of $5.32, indicating potential for prices above $2 in later years.
Current price is $0.9748 and market capitalization is $15.58M. The market rank is 5003.
RSI(14) is 20; SMA50 is $1.51 and SMA200 is $3.88. Support is at $0.975 and resistance at $1.79. The 30-day range is $0.7747 to $1.23, with an annualized volatility of 70%.
Tempest Therapeutics, Inc. Community Discussion
0Share your Tempest Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.